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1-Amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones, as previously unknown 
ring-annelated isoquinolines with a 3-aminoimidazolidin-4-one scaffold, were selectively 
prepared upon reacting 2-carbamoylmethyl- or 2-ethoxycarbonylmethyl-3,4-
dihydroisoquinolinium salts with hydrazine hydrate. Acylation of the primary amino group with 
benzoyl chlorides, followed by reductive ring cleavage of the annelated 4-imidazolidinone ring 
and final cyclodehydration of the N,N’-diacylhydrazines resulted in the synthesis of 1-methyl-2-
(5-aryl-[1,3,4]oxadiazol-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolines which are of interest due to 
their potential use as bioisosteres of biologically active N-aryl-2-(1-methyl-3,4-dihydro-1H-
isoquinolin-2-yl)acetamides. 
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Due to the natural occurrence and interesting chemical or biological properties of ring-annelated 
isoquinolines,1 as exemplified by the tetrahydroisoquinoline antitumor antibiotics,2 and 
lamellarin alkaloids,3 a broad interest in the synthesis of this class of azaheterocyclic compounds 
                                                 
† Postdoctoral Fellow of the Research Foundation – Flanders (FWO-Vlaanderen) 
Issue in Honor of Prof Henk C. van der Plas ARKIVOC 2009 (vi) 48-62 
ISSN 1551-7012 Page 49 ©ARKAT USA, Inc. 
exists.4 The tricyclic 1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones, which can be 
prepared via annelation of the imidazolidinone scaffold to 3,4-dihydroisoquinolines,5 allows 
further access to heterocyclic compounds with biological interest such as antidepressant activity.6 
Recently, we demonstrated that the hydrazides derived from 1-carbamoylmethyl-3H-indolinium 
salts selectively cyclize to 1-amino-1,2,3,9a-tetrahydroimidazo[1,2-a]indol-2(9H)-ones and that 
the corresponding six-membered ring systems, that is, 1,2,10,10a-tetrahydro[1,2,4]triazino[4,3-
a]indol-3(4H)-ones, by entering of the terminal NH2 group into reaction, are not formed.7 In an 
effort to broaden the scope of this regioselective ring-annelation reaction of hydrazides and to 
further expand the chemical space of ring-fused isoquinoline derivatives, the objective of this 
work is to investigate the synthesis of the unknown 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-
a]isoquinolin-2(3H)-ones and to study the transformation of the novel cyclic products to 1,3,4-
oxadiazoles. Considerable interest in the synthesis of substituted 1,3,4-oxadiazoles exists due to 
their numerous pharmacological properties, including analgesic, antiinflammatory, 
anticonvulsive, diuretic, antiemetic, hypnotic and sedative activities.8,9 More specific, 2-amino-
1,3,4-oxadiazoles act as muscle relaxants10 and possess antimitotic activity.11 
 
 
Results and Discussion 
 
As previously reported, the annelation of the imidazolidine ring to the isoquinoline nucleus starts 
by reaction of 3,4-dihydroisoquinoline or the corresponding 6,7-dimethoxy derivative with 
chloroacetamide which affords 2-carbamoylmethyl-3,4-dihydroisoquinolinium chloride 1.5c It 
was shown previously that the reaction of 2-carbamoylmethyl-3,4-dihydroisoquinolinium 
chloride 1 with aqueous potassium hydroxide afforded 10b-methyl-1,5,6,10b-
tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-one.5a During the present investigations, it was found 
that heating 2-carbamoylmethyl-3,4-dihydroisoquinolinium chlorides 1 in the presence of 
hydrazine hydrate regioselectively lead to the formation of five-membered heterocycles, i.e. 1-
amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones 3 in good yields, with 
hydrazines 2 as potential intermediates and without any observation of the corresponding six-
membered compounds 4 (Scheme 1). Similarly, 2-ethoxycarbonylmethyl-3,4-
dihydroisoquinolinium bromide 6, prepared by treatment of 1-methyl-3,4-dihydroisoquinoline 
with ethyl 2-bromoacetate,12 efficiently reacted with hydrazine hydrate under mild reaction 
conditions to afford 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones 3 
(Scheme 2). The main evidence for the assignment of structures 3a,b containing the 1-amino-4-
imidazolidinone ring, followed from the 15N NMR data. The 15N NMR spectrum showed three 
different N-atoms with chemical shifts at –341.7, –327.0 and –227.0 ppm (for compound 3a) and 
–342.1, –327.2 and –226.6 (for compound 3b). In 15N DEPT experiments without 1H-decoupling 
the central 15N NMR resonance (~ –327 ppm) showed a triplet multiplicity (1J = 68.9 Hz), thus 
unequivocally indicating the presence of an NH2 moiety. This definitely ruled out the 
corresponding six-membered structure 4, for which two NH substructures and a tertiary nitrogen 
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atom would be expected. Moreover, the 15N,1H-HMBC spectrum of compound 3a exhibited a 
clear correlation between the nitrogen atom with the largest chemical shift (N-1, δ = –227.0 
ppm) and the methyl protons of 10b-CH3 (δ = 1.70 ppm), what seems improbable with structure 
4 where the involved nuclei would be separated by four bonds and thus no correlation is 
expected. In addition, the 1H NMR spectra of compounds 3 contained only one sharp signal (at 
3.97 ppm for 3a and at 3.98 ppm for 3b) with a relative intensity of two protons attributed to the 
NH2-function. In contrast, for the corresponding six-membered structure 4, two different NH-
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 The assignments presented in Figures 1(a) and 2(a) were based on the combined application 
of standard NMR techniques such as NOE-difference (Figure 1(b) and 2(b)), NOESY, APT, 
DEPT, HSQC, HMBC and long-range INEPT spectra with selective excitation.13 
 As in the case of 1-amino-1,2,3,9a-tetrahydroimidazo[1,2-a]indol-2(9H)-ones,7 no other 
ring-chain tautomeric forms of 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-
ones (3a,b) were visible by 1H and 13C NMR in CDCl3 or DMSO-d6. Due to higher substitution 
and thereby higher conjugation, the tricyclic compound 3 is expected to be more favored than the 
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corresponding open-chain hydrazide. Nevertheless, by the action of protic acids on 1-amino-
1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones 3, a heterolytic cleavage of the N1-
C10b bond in the imidazolidine ring took place with formation of isoquinolinium salts 5. 
Formation of the latter was proven by NMR spectra of heterocycles 3 in deuterated 
trifluoroacetic acid. The appearance of a signal at 184.6 ppm (starting from compound 3a) and 
181.6 ppm (starting from compound 3b) in 13C NMR was indicative of a N+=C carbon and 

















































































Figure 1. (a) 1H (italics), 13C and 15N NMR (bold) chemical shifts [ppm; ref. TMS (1H and 13C) 























































































Figure 2. (a) 1H (italics), 13C and 15N NMR (bold) chemical shifts [ppm; ref. TMS (1H and 13C) 
and CH3NO2 (15N)] for 3b in CDCl3. (b) Relevant NOE correlations. 
 
 Further proof for the presence of the primary amino group in the cyclized compounds was 
obtained by reacting 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones 3 with 
benzoyl chlorides and benzaldehydes. Acylation of 3-amino-4-imidazolidinones 3 with benzoyl 
chlorides afforded N,N’-diacylhydrazines 7a-f in 67-96% yield. Further reduction of the latter 
compounds with sodium borohydride upon heating in tetrahydrofuran resulted in ring cleavage 
of the annelated 4-imidazolidinone ring,14 to give N,N’-diacylhydrazines 8a-f (Scheme 3). The 
latter easily underwent cyclodehydration to 1-methyl-2-(5-aryl-[1,3,4]oxadiazol-2-ylmethyl)-
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1,2,3,4-tetrahydroisoquinolines 9a-f under modified Appel conditions.15 The 2-(5-aryl-
[1,3,4]oxadiazol-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline moiety was present as a structural 
feature in compounds acting as urotensin-II receptor antagonists.16 1,3,4-Oxadiazoles are used as 
bioisosteres of amide functionalities in bioactive compounds,17 and, therefore, congeners 9 have 
potential for bioisosteric replacement of N-aryl-2-(1-methyl-3,4-dihydro-1H-isoquinolin-2-
yl)acetamides which act as antagonists of SNS sodium channels,18 inhibitors of voltage-gated 
sodium channels,19 and antiprotozoal agents.20 
 The exocyclic amino group in compounds 3 reacted with aromatic aldehydes by heating in 
ethanol in the presence of catalytic amounts of piperidine and afforded the corresponding 
hydrazones 10a-c, albeit in low yields. Compounds 10 could also be forced to reductive ring 




























7a (R = H, R1 = Ph, 85%)
7b (R = H, R1 = 3-Cl-C6H4, 67%)
7c (R = H, R1 = 4-F-C6H4, 96%)
7d (R = OCH3, R1 = Ph, 74%)
7e (R = OCH3, R1 = 3-Cl-C6H4, 95%)


















CH2Cl2, ∆, 24 h
3 equiv. NaBH4









3a (R = H)
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EtOH, ∆, 5 h
3 equiv. NaBH4
THF, ∆, 1 h
10a R = H, Ar = 4-Cl-C6H4 (15%)
10b R = H, Ar = 4-F-C6H4 (22%)









2-Carbamoylmethyl- or 2-ethoxycarbonylmethyl-3,4-dihydroisoquinolinium salts 
regioselectively cyclised to 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones 
upon treatment with hydrazine hydrate. The latter heterocyclic compounds occurred as single 
tautomeric forms and were the first ring-annelated isoquinolines with a 3-aminoimidazolidin-4-
one scaffold. The primary amino group was used as a handle via aroylation, reductive ring 
cleavage and cyclodehydration for further transformation to new 1,3,4-oxadiazoles which have 




Experimental Section  
 
General Procedures. Melting points were determined in open capillary tubes with a Büchi B-
540 melting point apparatus and are uncorrected. Infrared spectra were recorded on a Perkin 
Elmer Spectrum One spectrometer using potassium bromide pellets. 1H NMR spectra were 
recorded at 300 MHz on a Varian Unity Inova spectrometer and at 500 MHz on a Bruker Avance 
500 spectrometer; 13C NMR spectra were registered at 75 and 125 MHz, respectively. Chemical 
shifts, expressed in ppm, were relative to tetramethylsilane (TMS). 15N NMR spectra (50.69 
MHz) were obtained on a Bruker Avance 500 spectrometer using a ‘directly’ detecting 
broadband observe probe and were referenced against neat, external nitromethane (coaxial 
capillary). Mass spectra were recorded on a Agilent 110 (series MS with VL) instrument. 
Elemental analyses were measured with a CE-440 elemental analyzer, Model 440 CHN/O/S. For 
thin layer chromatographic (TLC) analyses, Merck precoated TLC plates (silica gel 60 F254) 
were used. 
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General procedures for the synthesis of 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-
a]isoquinolin-2(3H)-ones 3 
Procedure 1. A mixture of 1-methyl-2-carbamoylmethyl-3,4-dihydroisoquinolinium chloride 1 
(10 mmol) and hydrazine hydrate (55%, 10 mL) was heated at 70 °C for 5 h. The reaction 
mixture was cooled to room temperature, 10 ml of water was added and extraction was 
performed with dichloromethane (5 x 20 mL). The combined extracts were washed with water 
(25 mL) and dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo and the 
residue was chromatographed on silica gel with hexane/ethyl acetate/methanol 2:4:1 (for 3a) or 
dichloromethane/methanol 100:5 (for 3b) as eluent to yield 3. 
Procedure 2. A mixture of 2-carbamoylmethyl-3,4-dihydroisoquinolinium bromide 6 (10 mmol) 
and hydrazine hydrate (55%, 10 mL) was stirred at room temperature for 1 h. Water (10 mL) was 
added and extraction was performed with dichloromethane (5 x 20 mL). The combined extracts 
were washed with water (25 mL) and dried over anhydrous sodium sulfate. The solvent was 
evaporated in vacuo and the residue was chromatographed on silica gel with hexane/ethyl 
acetate/methanol 2:4:1 (for 3a) or dichloromethane/methanol 100:5 (for 3b) as eluent to yield 3. 
1-Amino-10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-one (3a). Yield 
82% (procedure 1), 88% (procedure 2). Mp 134-135 °C. 1H NMR (500 MHz, CDCl3): δ 1.70 
(3H, s, CH3), 2.63 (1H, m, 2J = 16.6 Hz, 3J5A = 4.3 Hz, 3J5B = 4.5 Hz, 6-CHB), 3.01 (1H, m, 2J = 
16.6 Hz, 3J5A = 9.6 Hz, 3J5B = 4.6 Hz, 6-CHA), 3.09 (1H, m, 2J = 13.4 Hz, 3J6A = 4.6 Hz, 3J6B = 
4.5 Hz, 5-CHB), 3.21 (1H, m, 2J = 13.4 Hz, 3J6A = 9.6 Hz, 3J6B = 4.3 Hz, 5-CHA), 3.58 (1H, A-
part of an AB-system, 2J = 15.0 Hz, 3-CHA), 3.46 (1H, B-part of an AB-system, 2J = 15.0 Hz, 3-
CHB), 3.97 (2H, s, NH2), 7.10 (1H, m, 7-CH), 7.21 (2H, m, 8-CH, 9-CH), 7.85 (1H, m, 10-CH). 
13C NMR (125 MHz, CDCl3): δ 24.1 (6-CH2), 26.4 (10b-CH3), 44.5 (5-CH2), 51.0 (3-CH2), 78.3 
(10b-C), 126.4 (9-C), 127.4 (10-C), 127.5 (8-C), 128.8 (7-C), 133.4 (6a-C), 136.8 (10a-C), 169.7 
(2-C). 15N NMR (50 MHz, CDCl3): –341.7 (4-N), –327.0 (t, J = 68.9 Hz, NH2), –227.0 (1-N). IR 
(KBr, cm-1): νN-H = 3300; νN-H = 3173; νC=O = 1716. MS m/z (%): 218 (M + H+, 100). Anal. 
Calcd for C12H15N3O: C 66.34; H 6.96; N 19.34. Found: C 65.99; H 6.36; N 19.54. 
1-Amino-8,9-dimethoxy-10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-a]isquinolin-2(3H)-
one (3b). Yield 90% (procedure 1), 71% (procedure 2). Mp 123-124 °C. 1H NMR (500 MHz, 
CDCl3): δ 1.66 (3H, s, CH3), 2.51 (1H, m, 2J = 16.4 Hz, 3J5A = 4.3 Hz, 3J5B = 4.5 Hz, 6-CHB), 
2.92 (1H, m, 2J = 16.4 Hz, 3J5A = 9.6 Hz, 3J5B = 4.6 Hz, 6-CHA), 3.06 (1H, m, 2J = 13.4 Hz, 3J6A 
= 4.6 Hz, 3J6B = 4.5 Hz, 5-CHB), 3.18 (1H, m, 2J = 13.4 Hz, 3J6A = 9.6 Hz, 3J6B = 4.3 Hz, 5-CHA), 
3.53 (1H, A-part of an AB-system, 2J = 15.0 Hz, 3-CHA), 3.42 (1H, B-part of an AB-system, 2J = 
15.0 Hz, 3-CHB), 3.83 (3H, s, 8-OCH3), 3.85 (3H, s, 9-OCH3), 3.98 (2H, s, NH2), 6.53 (1H, m, 7-
CH), 7.38 (1H, m, 10-CH). 13C NMR (125 MHz, CDCl3): δ 23.4 (6-CH2), 26.4 (10b-CH3), 44.3 
(5-CH2), 50.8 (3-CH2), 55.7 (8-OCH3), 55.9 (9-OCH3), 78.1 (10b-C), 110.0 (10-C), 110.7 (7-C), 
125.6 (6a-C), 128.9 (10a-C), 147.3 (9-C), 148.3 (8-C), 169.7 (2-C). 15N NMR (50 MHz, CDCl3): 
–342.1 (4-N), –327.2 (t, J = 68.9 Hz, NH2), –226.6 (1-N). IR (KBr, cm-1): νN-H = 3317; νN-H = 
3202; νC=O = 1712. MS m/z (%): 278 (M + H+, 100). Anal. Calcd for C14H19N3O3: C 60.63; H 
6.91; N 15.15. Found: C 60.86; H 6.76; N 14.80. 
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General procedure for the acylation of 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-
a]isoquinolin-2(3H)-ones 3 with benzoyl chlorides  
To a stirred solution of 3 (10 mmol) in dry acetonitrile (7.5 mL), a solution of benzoyl chloride 
(11 mmol) in dry acetonitrile (10 mL) was added dropwise at room temperature and the mixture 
was stirred for 1 hour. The formed crystals were separated by filtration and dissolved in water 
(25 mL). Solid NaHCO3 was added in portions to basify the mixture to pH 8-9. The mixture was 
extracted with dichloromethane (3 × 25 mL), the combined extracts were washed with water (25 
mL) and dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo and the 
residue was purified by flash chromatography with acetone/hexane 1:1 (for 7a-c) or 
dichloromethane/methanol 9:1 (for 7d-f) to give the corresponding N,N’-diacylhydrazines 7.  
N-(10b-Methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-1(5H)-yl)benzamide 
(7a). Yield 85%. Mp 82 °C. 1H NMR (300 MHz, CDCl3): δ 1.69 (3H, s, 10b-CH3), 2.63-3.08 
(5H, m, 2×CH2 and CH(H)), 3.59 (1H, d, J = 15.8 Hz, CH(H)), 7.09-7.77 (9H, m, aromatic 
protons), 9.21 (1H, s, NH). 13C NMR (75 MHz, CDCl3): δ 24.8 (CH2), 26.2 (10b-CH3), 45.4 
(CH2), 51.4 (CH2), 80.3 (C), 126.5, 127.1, 127.5 (2×CH), 127.8, 128.4 (2×CH), 128.8, 131.1, 
132.1, 133.6 (Ar-C), 166.1 (C=O), 170.3 (C=O). IR (KBr, cm-1): νN-H = 3250; νC=O = 1723; νC=O 
= 1686. MS m/z (%): 322 (M + H+, 100). Anal. Calcd for C19H19N3O2: C 71.01; H 5.96; N 13.08. 
Found: C 71.18; H 5.98; N 12.71. 
3-Chloro-N-(10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-1(5H)-
yl)benzamide (7b). Yield 67%. Mp 162 °C. 1H NMR (300 MHz, CDCl3): δ 1.69 (3H, s, 10b-
CH3), 2.64-3.09 (5H, m, 2×CH2 and CH(H)), 3.60 (1H, d, J = 15.8 Hz, CH(H)), 7.10-7.69 (8H, 
m, aromatic protons), 9.47 (1H, s, NH). 13C NMR (75 MHz, CDCl3): δ 24.6 (CH2), 26.1 (10b-
CH3), 45.3 (CH2), 51.3 (CH2), 80.4 (C), 125.1, 126.6, 127.1, 127.9, 128.1, 128.8, 129.7, 132.2, 
132.4, 133.5, 134.6 (Ar-C), 164.4 (C=O), 170.3 (C=O). IR (KBr, cm-1): νN-H = 3193; νC=O = 
1721; νC=O = 1691. MS m/z (%): 356/58 (M + H+, 100). Anal. Calcd for C19H18ClN3O2: C 64.13; 
H 5.10; N 11.81. Found: C 64.50; H 5.07; N 11.43. 
4-Fluoro-N-(10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-1(5H)-
yl)benzamide (7c). Yield 96%. Mp 94 °C. 1H NMR (300 MHz, CDCl3): δ 1.67 (3H, s, 10b-
CH3), 2.59-3.12 (5H, m, 2×CH2 and CH(H)), 3.55 (1H, d, J = 15.8 Hz, CH(H)), 6.89 – 7.80 (8H, 
m, aromatic protons), 9.46 (1H, s, NH). 13C NMR (75 MHz, CDCl3): δ 24.5 (CH2), 26.1 (10b-
CH3), 44.9 (CH2), 51.1 (CH2), 80.3 (C), 115.4 (d, J = 21.9 Hz, Ph 3,5-C), 126.6, 126.9 (d, J = 2.5 
Hz, 1-C), 127.2, 127.9, 128.8, 129.9 (d, J = 9.1 Hz, Ph 2,6-C), 133.5, 164.9 (d, J = 252.9 Hz, Ph 
4-C), 164.7 (C=O), 170.6 (C=O). IR (KBr, cm-1): νN-H = 3250; νC=O = 1722; νC=O = 1686. MS m/z 
(%): 340 (M + H+, 100). Anal. Calcd for C19H18FN3O2: C 67.24; H 5.35; N 12.38. Found: C 
67.63; H 5.57; N 12.15.  
N-(8,9-Dimethoxy-10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-1(5H)-
yl)benzamide (7d). Yield 74%. Mp 93 °C. 1H NMR (300 MHz, CDCl3): δ 1.66 (3H, s, 10b-
CH3), 2.49-3.09 (5H, m, 2×CH2 and CH(H)), 3.53 (1H, d, J = 15.5 Hz, CH(H)), 3.77 (3H, s, 
CH3), 3.86 (3H, s, CH3), 6.54 (1H, s, C7-H), 6.85 (1H, s, C10-H), 7.18-7.24 (2H, m, C3’-H and 
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C5’-H), 7.32-7.37 (1H, m, C4’-H), 7.74-7.76 (2H, m, C2’-H and C6’-H), 9.63 (1H, s, NH). 13C 
NMR (75 MHz, CDCl3): δ 24.0 (CH2), 26.3 (10b-CH3), 45.2 (CH2), 50.9 (CH2), 55.9 (CH3), 56.1 
(CH3), 80.4 (C), 109.9, 110.9, 125.7, 127.7 (2×CH), 128.7 (2×CH), 130.9, 132.4, 147.7, 148.7 
(Ar-C), 166.3 (C=O), 170.9 (C=O). IR (KBr, cm-1): νN-H = 3245; νC=O = 1720; νC=O = 1684. MS 
m/z (%): 382 (M + H+, 100). Anal. Calcd for C21H23N3O4: C 66.13; H 6.08; N 11.02. Found: C 
66.49; H 6.46; N 11.04. 
3-Chloro-N-(8,9-dimethoxy-10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquino-
lin-1(5H)-yl)benzamide (7e). Yield 95%. Mp 105 °C. 1H NMR (300 MHz, CDCl3): δ 1.64 (3H, 
s, 10b-CH3), 2.48-3.13 (5H, m, 2×CH2 and CH(H)), 3.53 (1H, d, J = 15.6 Hz, CH(H)), 3.79 (3H, 
s, CH3), 3.86 (3H, s, CH3), 6.53 (1H, s, C7-H), 6.81 (1H, s, C10-H), 7.15-7.21 (1H, m, C5’-H), 
7.34-7.38 (1H, m, C4’-H), 7.67-7.69 (2H, m, C2’-H, C6’-H), 9.87 (1H, s, NH). 13C NMR (75 
MHz, CDCl3): δ 23.5 (CH2), 25.9 (10b-CH3), 44.7 (CH2), 50.4 (CH2), 55.6 (CH3), 55.8 (CH3), 
80.2 (C), 109.6, 110.7, 124.8, 125.4, 128.2, 129.6, 132.1, 132.2, 134.7, 147.4, 148.5 (Ar-C), 
164.4 (C=O), 170.8 (C=O). IR (KBr, cm-1): νN-H = 3194; νC=O = 1721; νC=O = 1686. MS m/z (%): 
416/18 (M + H+, 100). Anal. Calcd for C21H22ClN3O4: C 60.65; H 5.33; N 10.10. Found: C 
60.32; H 5.88; N 9.86. 
4-Fluoro-N-(8,9-dimethoxy-10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquino-
lin-1(5H)-yl)benzamide (7f). 76% yield. Mp 111 °C. 1H NMR (300 MHz, CDCl3): δ 1.64 (3H, 
s, 10b-CH3), 2.47-3.14 (5H, m, 2×CH2 and CH(H)), 3.51 (1H, d, J = 15.6 Hz, CH(H)), 3.79 (3H, 
s, CH3), 3.86 (3H, s, CH3), 6.53 (1H, s, C7-H), 6.81 (1H, s, C10-H), 6.86-6.91 (2H, m, C3’-H and 
C5’-H), 7.77-7.82 (2H, m, C2’-H and C6’-H), 9.81 (1H, s, NH). 13C NMR (75 MHz, CDCl3): δ 
23.4 (CH2), 25.8 (10b-CH3), 44.5 (CH2), 50.3 (CH2), 55.6 (CH3), 55.8 (CH3), 80.1 (C), 109.6, 
110.6, 115.4 (d, J = 21.9 Hz, 2×CH), 125.3, 126.7 (d, J = 2.4 Hz, Ph 1-C), 129.9 (br d, J = 8.9 
Hz, Ph 2,6-C), 147.4, 148.4, 164.9 (d, J = 253.2 Hz, Ph 4-C) (Ar-C), 164.7 (C=O), 170.9 (C=O). 
IR (KBr, cm-1): νN-H = 3250; νC=O = 1718; νC=O = 1685. MS m/z (%): 400 (M + H+, 100). Anal. 
Calcd for C21H22FN3O4: C 63.15; H 5.55; N 10.52. Found: C 63.41; H 5.83; N 10.75. 
 
General procedure for the reduction of N-substituted 1-amino-1,5,6,10b-
tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones (7a-f, 10a,b) with sodium borohydride 
To a solution of N-substituted 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-
one 7 or 10 (1.35 mmol) in 7 mL of dry tetrahydrofuran, sodium borohydride (0.153 g, 4.05 
mmol) was added. The mixture was heated at 70 °C for one hour, then cooled to room 
temperature, poured into water (30 mL) and extracted with dichloromethane (3 × 20 mL). The 
combined extracts were washed with water (20 mL) and dried over sodium sulfate. After 
filtration, the solvent was removed under reduced pressure and the residue purified by flash 
chromatography on silica gel with acetone/hexane 1:1 (for 8a-f) or acetone/hexane 1:3 (for 
11a,b) to obtain the various hydrazines 8 and 11. 
N'-[2-(1-Methyl-3,4-dihydro-2(1H)-isoquinolinyl)acetyl]benzohydrazide (8a). Yield 65%. 
Mp 115 °C. 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, d, J = 6.6 Hz, CH3), 2.71-3.10 (4H, m, 
2×CH2), 3.27 (1H, d, J = 15.6 Hz, CH(H)), 3.37 (1H, d, J = 15.6 Hz, CH(H)), 3.95 (1H, q, J = 
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6.6 Hz, CH), 6.10-7.91 (9H, m, aromatic protons), 9.76 (1H, s, NH), 10.39 (1H, s, NH). 13C 
NMR (75 MHz, DMSO-d6): δ 19.5 (CH3), 27.3 (CH2), 44.8 (CH2), 56.3 (CH), 56.5 (CH2), 125.6, 
125.8, 127.2, 127.5 (2×CH), 128.5 (2×CH), 128.6, 131.8, 132.5, 133.9, 139.8 (Ar-C), 165.3 
(C=O), 169.6 (C=O). IR (KBr, cm-1): νN-H = 3172; νC=O = 1698; νC=O = 1645. MS m/z (%): 324 
(M + H+, 100). Anal. Calcd for C19H21N3O2: C 70.57; H 6.55; N 12.99. Found: C 70.19; H 6.67; 
N 12.77. 
3-Chloro-N'-[(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)acetyl]benzohydrazide (8b). Yield 
85%. Mp 149 °C. 1H NMR (300 MHz, DMSO-d6): δ 1.32 (3H, d, J = 6.6 Hz, CH3), 2.69-3.09 
(4H, m, 2×CH2), 3.28 (1H, d, J = 15.6 Hz, CH(H)), 3.37 (1H, d, J = 15.6 Hz, CH(H)), 3.94 (1H, 
q, J = 6.6 Hz, CH), 7.08-7.93 (8H, m, aromatic protons), 9.82 (1H, s, NH), 10.54 (1H, s, NH). 
13C NMR (75 MHz, DMSO-d6): δ 19.5 (CH3), 27.3 (CH2), 44.8 (CH2), 56.3 (CH), 56.6 (CH2), 
125.6, 125.8, 126.2, 127.1, 127.3, 128.6, 130.6, 131.7, 133.3, 133.9, 134.5, 139.8 (Ar-C), 163.9 
(C=O), 169.6 (C=O). IR (KBr, cm-1): νN-H = 3213; νC=O = 1700; νC=O = 1646. MS m/z (%): 
358/60 (M + H+, 100). Anal. Calcd for C19H20ClN3O2: C 63.77; H 5.63; N 11.74. Found: C 
64.02; H 5.65; N 11.62. 
4-Fluoro-N'-[2-(1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)acetyl]benzohydrazide (8c). 
Yield 82%. Mp 106 °C. 1H NMR (300 MHz, DMSO-d6): δ 1.32 (3H, d, J = 6.6 Hz, CH3), 2.69-
3.10 (4H, m, 2×CH2), 3.27 (1H, d, J = 15.6 Hz, CH(H)), 3.37 (1H, d, J = 15.6 Hz, CH(H)), 3.94 
(1H, q, J = 6.6 Hz, CH), 7.07-7.99 (8H, m, aromatic protons), 9.78 (1H, s, NH), 10.44 (1H, s, 
NH). 13C NMR (75 MHz, DMSO-d6): δ 19.5 (CH3), 27.3 (CH2), 44.8 (CH2), 56.3 (CH), 56.6 
(CH2), 115.5 (d, J = 21.9 Hz, Ph 3,5-C), 125.6, 125.8, 127.1, 128.6, 128.9 (d, J = 2.8 Hz, Ph 1-
C), 130.2 (d, J = 9.4 Hz, Ph 2,6-C), 133.9, 139.8, 164.2 (d, J = 249.3 Hz, Ph 4-C), 164.3 (C=O), 
169.6 (C=O). IR (KBr, cm-1): νN-H = 3252; νC=O = 1701; νC=O = 1650. MS m/z (%): 342 (M + H+, 
100). Anal. Calcd for C19H20FN3O2: C 66.85; H 5.91; N 12.31. Found: C 66.48; H 6.16; N 12.30. 
N'-[2-(6,7-Dimethoxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)acetyl]benzohydrazide 
(8d). Yield 61%. Mp 69 °C. 1H NMR (300 MHz, CDCl3): δ 1.47 (3H, d, J = 6.6 Hz, CH3), 2.65-
3.25 (4H, m, 2×CH2), 3.37 (2H, s, CH2), 3.83 (3H, s, CH3), 3.84 (3H, s, CH3), 3.81-3.88 (1H, m, 
CH), 6.53 (1H, s, C5-H), 6.58 (1H, s, C8-H), 7.35-7.40 (2H, m, C3’-H and C5’-H), 7.46-7.51 (1H, 
m, C4’-H), 7.79-7.82 (2H, m, C2’-H and C6’-H), 9.55 (2H, br s, 2×NH). 13C NMR (75 MHz, 
CDCl3): δ 20.5 (CH3), 26.7 (CH2), 45.2 (CH2), 55.8 (CH3), 55.9 (CH3), 57.0 (CH), 57.2 (CH2), 
109.9, 111.3, 125.2, 127.2 (2×CH), 128.5 (2×CH), 130.6, 131.3, 132.2, 147.3, 147.5 (Ar-C), 
164.7 (C=O), 168.8 (C=O). IR (KBr, cm-1): νN-H = 3279; νC=O = 1703; νC=O = 1657. MS m/z (%): 
384 (M + H+, 100). Anal. Calcd for C21H25N3O4: C 65.78; H 6.57; N 10.96. Found: C 65.70; H 
6.94; N 11.33. 
3-Chloro-N'-[2-(6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)acetyl]benzo-
hydrazide (8e). Yield 69%. 1H NMR (300 MHz, CDCl3): δ 1.42 (3H, d, J = 6.5 Hz, CH3), 2.65-
3.24 (4H, m, 2×CH2), 3.38 (2H, s, CH2), 3.840 (3H, s, CH3), 3.843 (3H, s, CH3), 3.81-3.89 (1H, 
m, CH), 6.53 (1H, s, C5-H), 6.58 (1H, s, C8-H), 7.27-7.78 (4H, m, aromatic protons), 10.09 (2H, 
br s, 2×NH). 13C NMR (75 MHz, CDCl3): δ 20.5 (CH3), 26.6 (CH2), 45.1 (CH2), 55.8 (CH3), 
55.9 (CH3), 56.9 (CH), 57.2 (CH2), 109.9, 111.3, 125.1, 125.3, 127.7, 129.8, 130.5, 132.1, 132.9, 
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134.6, 147.3, 147.5 (Ar-C), 163.4 (C=O), 169.3 (C=O). IR (KBr, cm-1): νN-H = 3279; νC=O = 
1701; νC=O = 1659. MS m/z (%): 418/20 (M + H+, 100). Anal. Calcd for C21H24ClN3O4: C 60.36; 
H 5.79; N 10.06. Found: C 60.37; H 5.59; N 9.68. 
4-Fluoro-N'-[2-(6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)acetyl]benzo-
hydrazide (8f). Yield 80%. Mp 161 °C. 1H NMR (300 MHz, CDCl3): δ 1.39 (3H, d, J = 6.6 Hz, 
CH3), 2.63-3.22 (4H, m, 2×CH2), 3.32 (1H, d, J = 17.1 Hz, CH(H)), 3.38 (1H, d, J = 16.9 Hz, 
CH(H)), 3.82 (6H, s, 2×CH3), 3.81-3.87 (1H, m, CH), 6.52 (1H, s, C7-H), 6.56 (1H, s, C10-H), 
6.97-7.03 (2H, m, C3’-H and C5’-H), 7.77-7.82 (2H, m, C2’-H and C6’-H), 9.98 (2H, br s, 2×NH). 
13C NMR (75 MHz, CDCl3): δ 20.4 (CH3), 26.6 (CH2), 45.1 (CH2), 55.8 (CH3), 55.9 (CH3), 57.0 
(CH), 57.2 (CH2), 109.9, 111.3, 115.5 (d, J = 21.9 Hz, Ph 3,5-C), 125.1, 127.3 (d, J = 2.5 Hz, Ph 
1-C), 129.7 (d, J = 8.8 Hz, Ph 2,6-C), 130.5, 147.3, 147.5, 164.9 (d, J = 253.3 Hz, Ph 4-C), 163.9 
(C=O), 169.6 (C=O). IR (KBr, cm-1): νN-H = 3254; νC=O = 1694; νC=O = 1650. MS m/z (%): 402 
(M + H+, 100). Anal. Calcd for C21H24FN3O4: C 62.83; H 6.03; N 10.47. Found: C 62.52; H 
6.41; N 10.18. 
N'-[(1E)-(4-Chlorophenyl)methylene]-2-(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)aceto-
hydrazide (11a). Yield 24%. Oil. 1H NMR (300 MHz, CDCl3): δ 1.39 (3H, d, J = 6.7 Hz, CH3), 
2.28-3.19 (4H, m, 2×CH2), 3.37 (1H, d, J = 17.1 Hz, CH(H)), 3.43 (1H, d, J = 17.1 Hz, CH(H)), 
3.92 (1H, q, J = 6.7 Hz, CH), 7.06-7.69 (8H, m, aromatic protons), 8.12 (1H, s, NH), 10.34 (1H, 
s, N=CH). 13C NMR (75 MHz, CDCl3): δ 19.6 (CH3), 27.9 (CH2), 45.5 (CH2), 57.5 (CH), 57.9 
(CH2), 126.1, 126.4, 127.1, 128.8 (2×CH), 128.9 (2×CH), 132.0, 133.0, 136.4, 138.9, 147.0 (Ar-
C), 147.0 (C=N), 167.2 (C=O). IR (KBr, cm-1): νN-H = 3207; νC=O = 1679; νC=N = 1596. MS m/z 
(%): 342/44 (M + H+, 100). Anal. Calcd for C19H20ClN3O: C 66.76; H 5.90; N 12.29. Found: C 
66.43; H 5.75; N 11.93. 
N'-[(1E)-(4-Fluorophenyl)methylene]-2-(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)aceto-
hydrazide (11b). Yield 24%. Oil. 1H NMR (300 MHz, CDCl3): δ 1.41 (3H, d, J = 6.7 Hz, CH3), 
2.78-3.20 (4H, m, 2×CH2), 3.40 (2H, s, CH2), 3.93 (1H, q, J = 6.6 Hz, CH), 7.03-7.76 (8H, m, 
aromatic protons), 8.13 (1H, s, NH), 10.33 (1H, s, N=CH). 13C NMR (75 MHz, CDCl3): δ 19.7 
(CH3), 27.9 (CH2), 45.5 (CH2), 57.5 (CH), 57.8 (CH2), 115.8 (d, J = 21.9 Hz, Ph 3,5-C), 126.1, 
126.4, 127.2, 128.9, 129.5 (d, J = 8.6 Hz, Ph 2,6-C), 129.7 (d, J = 3.5 Hz, Ph 1-C), 133.0, 138.9, 
147.2 (C=N), 164.1 (d, J = 251.0 Hz, Ph 4-C), 167.1 (C=O). IR (KBr, cm-1): νN-H = 3212; νC=O = 
1682; νC=N = 1603. MS m/z (%): 326 (M + H+, 100). Anal. Calcd for C19H20FN3O: C 70.13; H 
6.20; N 12.91. Found: C 69.85; H 6.43; N 12.87. 
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General procedure for the synthesis of 1-methyl-2-(5-aryl-[1,3,4]oxadiazol-2-ylmethyl)-
1,2,3,4-tetrahydroisoquinolines (9a-f) 
To a stirred suspension of hydrazide 9 (1 mmol) in dichloromethane (12 mL) was added 
triphenylphosphine (1.57 mmol), carbon tetrachloride (5 mmol) and triethylamine (1.57 mmol), 
after which the mixture was heated to reflux for 24 h. The mixture was cooled to room 
temperature, poured into water (15 mL) and extracted with dichloromethane (3 × 15 mL). The 
combined organic layers were dried over sodium sulfate, filtered and the solvent was evaporated 
under reduced pressure. The residue was chromatographed on silica gel with hexane/acetone 2:1 
to yield 1,3,4-oxadiazoles 9 as oils. 
1-Methyl-2-(5-phenyl-[1,3,4]oxadiazol-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline (9a). 
Yield 42%. 1H NMR (300 MHz, DMSO-d6): δ 1.34 (3H, d, J = 6.6 Hz, CH3), 2.69 – 3.17 (4H, 
m, 2×CH2), 3.92 (1H, q, J = 6.5 Hz, CH), 4.07 (1H, d, J = 15.1 Hz, CH(H)), 4.17 (1H, d, J = 
15.1 Hz, CH(H)), 7.07 – 8.02 (9H, m, aromatic protons). 13C NMR (75 MHz, DMSO-d6): δ 19.4 
(CH3), 27.3 (CH2), 44.6 (CH2), 47.6 (CH2), 55.5 (CH), 123.3, 125.6, 125.7, 126.4 (2×CH), 127.0, 
128.5, 129.4 (2×CH), 131.8, 135.5, 139.3 (Ar-C), 164.3, 164.4 (C-O-C). IR (KBr, cm-1): νC=N = 
1609. MS m/z (%): 306 (M + H+, 100). Anal. Calcd for C19H19N3O: C 74.73; H 6.27; N 13.76. 
Found: C 74.76; H 6.32; N 13.70. 
2-[5-(3-Chlorophenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1-methyl-1,2,3,4-tetrahydroisoquinoline 
(9b). Yield 68%. 1H NMR (300 MHz, DMSO-d6): δ 1.37 (3H, d, J = 6.6 Hz, CH3), 2.71 – 3.20 
(4H, m, 2×CH2), 3.93 (1H, q, J = 6.6 Hz, CH), 4.10 (1H, d, J = 15.1 Hz, CH(H)), 4.20 (1H, d, J 
= 15.1 Hz, CH(H)), 7.08 – 7.98 (8H, m, aromatic protons). 13C NMR (75 MHz, DMSO-d6): δ 
19.5 (CH3), 27.3 (CH2), 44.7 (CH2), 47.7 (CH2), 55.6 (CH), 125.2, 125.3, 125.7, 125.8, 125.9, 
127.1, 128.6, 131.5, 131.8, 133.6, 134.0, 139.4 (Ar-C), 163.3, 164.9 (C-O-C). IR (KBr, cm-1): 
νC=N = 1606. MS m/z (%): 340/42 (M + H+, 100). Anal. Calcd for C19H18ClN3O: C 67.15; H 
5.34; N 12.37. Found: C 66.78; H 4.99; N 12.19. 
2-[5-(4-Fluorophenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1-methyl-1,2,3,4-tetrahydroisoquinoline 
(9c). Yield 77%. 1H NMR (300 MHz, DMSO-d6): δ 1.36 (3H, d, J = 6.6 Hz, CH3), 2.68 – 3.17 
(4H, m, 2×CH2), 3.92 (1H, q, J = 6.6 Hz, CH), 4.09 (1H, d, J = 15.1 Hz, CH(H)), 4.19 (1H, d, J 
= 15.1 Hz, CH(H)), 7.08 – 8.08 (8H, m, aromatic protons). 13C NMR (75 MHz, DMSO-d6): δ 
19.5 (CH3), 27.3 (CH2), 44.7 (CH2), 47.7 (CH2), 55.5 (CH), 116.7 (d, J = 22.5 Hz, Ph 3,5-C), 
120.1 (d, J = 3.6 Hz, Ph 1-C), 125.7, 125.8, 127.1, 128.6, 129.2 (d, J = 9.5 Hz, Ph 2,6-C), 133.6, 
139.4, 164.1 (d, J = 250.2 Hz, Ph 4-C), 163.7, 164.5 (C-O-C). IR (KBr, cm-1): νC=N = 1610. MS 
m/z (%): 324 (M + H+, 100). Anal. Calcd for C19H18FN3O: C 70.57; H 5.61; N 12.99. Found: C 
70.32; H 5.33; N 12.74. 
6,7-Dimethoxy-1-methyl-2-(5-phenyl-[1,3,4]oxadiazol-2-ylmethyl)-1,2,3,4-tetrahydroiso-
quinoline (9d). Yield 52%. 1H NMR (300 MHz, CDCl3): δ 1.45 (3H, d, J = 6.6 Hz, CH3), 2.67 – 
3.27 (4H, m, 2×CH2), 3.83 (6H, s, 2×CH3), 3.90 (1H, q, J = 6.6 Hz, CH), 4.08 (1H, d, J = 14.7 
Hz, CH(H)), 4.16 (1H, d, J = 14.7 Hz, CH(H)), 6.55 (1H, s, C5-H), 6.56 (1H, s, C8-H), 7.46-7.55 
(3H, m, C3’-H, C4’-H and C5’-H), 8.05-8.08 (2H, m, C2’-H and C6’-H). 13C NMR (75 MHz, 
CDCl3): δ 20.1 (CH3), 26.6 (CH2), 45.2 (CH2), 48.2 (CH2), 55.8 (CH), 55.9 (CH3), 56.0 (CH3), 
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109.9, 111.2, 123.7, 125.4, 126.9 (2×CH), 128.9 (2×CH), 130.7, 131.7, 147.3, 147.4 (Ar-C), 
164.2, 165.4 (C-O-C). IR (KBr, cm-1): νC=N = 1610. MS m/z (%): 366 (M + H+, 100). Anal. Calcd 
for C21H23N3O3: C 69.02; H 6.34; N 11.50. Found: C 69.35; H 6.28; N 11.23. 
2-[5-(3-Chlorophenyl)-[1,3,4]oxadiazol-2-ylmethyl]-6,7-dimethoxy-1-methyl-1,2,3,4-tetra-
hydroisoquinoline (9e). Yield 82%. 1H NMR (300 MHz, CDCl3): δ 1.44 (3H, d, J = 6.6 Hz, 
CH3), 2.66 – 3.26 (4H, m, 2×CH2), 3.82 (6H, s, 2×CH3), 3.88 (1H, q, J = 6.6 Hz, CH), 4.06 (1H, 
d, J = 14.8 Hz, CH(H)), 4.15 (1H, d, J = 14.8 Hz, CH(H)), 6.55 (1H, s, C5-H), 6.56 (1H, s, C8-
H), 7.40-7.51 (2H, m, C4’-H and C5’-H), 7.97-8.04 (2H, m, C2’-H and C6’-H). 13C NMR (75 
MHz, CDCl3): δ 20.1 (CH3), 26.6 (CH2), 45.2 (CH2), 48.2 (CH2), 55.8 (CH), 55.9 (CH3), 56.1 
(CH3), 110.1, 111.2, 125.0, 125.4, 126.9, 130.3, 130.7, 131.8, 135.1, 147.4, 147.5 (Ar-C), 164.2, 
164.6 (C-O-C). IR (KBr, cm-1): νC=N = 1611. MS m/z (%): 400/02 (M + H+, 100). Anal. Calcd for 
C21H22ClN3O3: C 63.08; H 5.55; N 10.51. Found: C 63.33; H 5.45; N 10.63. 
2-[5-(4-Fluorophenyl)-[1,3,4]oxadiazol-2-ylmethyl]-6,7-dimethoxy-1-methyl-1,2,3,4-
tetrahydroisoquinoline (9f). Yield 87%. 1H NMR (300 MHz, CDCl3): δ 1.45 (3H, d, J = 6.6 
Hz, CH3), 2.67 – 3.27 (4H, m, 2×CH2), 3.83 (6H, s, 2×CH3), 3.89 (1H, q, J = 6.6 Hz, CH), 4.06 
(1H, d, J = 14.7 Hz, CH(H)), 4.14 (1H, d, J = 14.7 Hz, CH(H)), 6.55 (1H, s, C5-H), 6.56 (1H, s, 
C8-H), 7.15-7.22 (2H, m, C3’-H and C5’-H), 8.03-8.10 (2H, m, C2’-H and C6’-H). 13C NMR (75 
MHz, CDCl3): δ 20.1 (CH3), 26.5 (CH2), 45.1 (CH2), 48.1 (CH2), 55.8 (CH), 55.9 (CH3), 56.1 
(CH3), 109.9, 111.1, 116.3 (d, J = 22.1 Hz, Ph 3,5-C), 120.1 (d, J = 3.3 Hz, Ph 1-C), 125.3, 129.2 
(d, J = 9.2 Hz, Ph 2,6-C), 130.6, 147.3, 147.4, 164.7 (d, J = 253.5 Hz, Ph 4-C), 164.2, 164.6 (C-
O-C). IR (KBr, cm-1): νC=N = 1607. MS m/z (%): 384 (M + H+, 100). Anal. Calcd for 
C21H22FN3O3: C 65.78; H 5.78; N 10.96. Found: C 65.49; H 5.76; N 10.64. 
 
General procedure for the condensation of 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-
a]isoquinolin-2(3H)-ones 3 with aromatic aldehydes  
To a solution of amine 3 (4 mmol) and 4-substituted benzaldehyde (4.4 mmol) in absolute 
ethanol (20 mL), 3 drops of piperidine were added and the mixture was refluxed for 5 h. 
Evaporation of the solvent gave a residue, which was chromatographed on silica gel with hexane 
/acetone 3:1 (for 10a, b) or dichloromethane/methanol 9:1 (for 10c) to give the corresponding 
hydrazones 10.  
1-[(4-Chlorobenzylidene)amino]-10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquino-
lin-2(3H)-one (10a). Yield 15%. Mp 150 °C. 1H NMR (300 MHz, CDCl3): δ 1.89 (3H, s, CH3), 
2.64 – 3.38 (4H, m, 2×CH2), 3.60 (1H, d, J = 15.2 Hz, CH(H)), 3.68 (1H, d, J = 15.2 Hz, 
CH(H)), 7.10 – 7.81 (8H, m, aromatic protons), 9.58 (1H, s, N=CH). 13C NMR (75 MHz, 
CDCl3): δ 23.6 (CH2), 27.9 (CH3), 43.9 (CH2), 52.0 (CH2), 80.3 (C), 126.5, 127.6, 127.8, 128.5 
(2×CH), 128.8, 128.9 (2×CH), 133.2, 133.8, 136.2, 136.9 (Ar-C), 152.3 (C=N), 167.6 (C=O). IR 
(KBr, cm-1): νC=O = 1703; νC=N = 1599. MS m/z (%): 340/42 (M + H+, 100). Anal. Calcd for 
C19H18ClN3O: C 67.15; H 5.34; N 12.37. Found: C 66.96; H 5.44; N 12.48. 
1-[(4-Fluorobenzylidene)amino]-10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquino-
lin-2(3H)-one (10b). Yield 22%. Mp 115 °C. 1H NMR (300 MHz, CDCl3): δ 1.98 (3H, s, CH3), 
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2.73 – 3.47 (4H, m, 2×CH2), 3.68 (1H, d, J = 15.2 Hz, CH(H)), 3.76 (1H, d, J = 15.2 Hz, 
CH(H)), 7.18 – 7.91 (8H, m, aromatic protons), 9.62 (1H, s, N=CH). 13C NMR (75 MHz, 
CDCl3): δ 23.6 (CH2), 27.7 (CH3), 43.8 (CH2), 51.9 (CH2), 80.2 (C), 115.7 (d, J = 21.9 Hz, Ph 
3,5-C), 126.4, 127.5, 127.7, 128.6, 129.1 (d, J = 8.5 Hz, Ph 2,6-C), 131.3 (d, J = 2.7 Hz, Ph 1-C), 
133.1, 136.8 (Ar-C), 152.6 (C=N), 163.9 (d, J = 251.1 Hz, Ph 4-C), 167.3 (C=O). IR (KBr, cm-
1): νC=O = 1703; νC=N = 1601. MS m/z (%): 324 (M + H+, 100). Anal. Calcd for C19H18FN3O: C 
70.57; H 5.61; N 12.99. Found: C 70.96; H 5.30; N 12.88. 
1-[(4-Chlorobenzylidene)amino]-8,9-dimethoxy-10b-methyl-1,5,6,10b-tetrahydroimidazo 
[2,1-a]isoquinolin-2(3H)-one (10c). Yield 8%. Oil. 1H NMR (300 MHz, CDCl3): δ 1.86 (3H, s, 
CH3), 2.87 – 3.34 (4H, m, 2×CH2), 3.56 (1H, d, J = 15.2 Hz, CH(H)), 3.64 (1H, d, J = 15.2 Hz, 
CH(H)), 3.74 (3H, s, CH3), 3.82 (3H, s, CH3), 6.53 – 7.71 (6H, m, aromatic protons), 9.68 (1H, s, 
N=CH). 13C NMR (75 MHz, CDCl3): δ 23.0 (CH3), 27.8 (CH2), 43.8 (CH2), 51.8 (CH2), 55.6 
(CH3), 55.7 (CH3), 80.1 (C), 110.2, 110.7, 125.5, 128.1 (2×CH), 128.8, 128.9 (2×CH), 133.7, 
136.2, 147.4, 148.4 (Ar-C), 152.0 (C=N), 167.5 (C=O). IR (KBr, cm-1): νC=O = 1703; νC=N = 
1603. MS m/z (%): 400 (M + H+, 100). Anal. Calcd for C21H22ClN3O3: C 63.08; H 5.55; N 10.51. 





The authors are indebted to the Research Foundation - Flanders (FWO-Vlaanderen) for financial 





1. For some reviews on isoquinolines, see: (a) Bentley, K. W. The Isoquinoline Alkaloids; 
Harwood Academic Publishers: Amsterdam, 1998. (b) Bentley, K. W. Nat. Prod. Rep. 2005, 
22, 249. (c) Bentley, K. W. Nat. Prod. Rep. 2006, 23, 444. (d) Chrzanowska, M.; 
Rozwadowska, M. D. Chem. Rev. 2004, 104, 3341. 
2. Scott, J. D.; Williams, R. M. Chem. Rev. 2002, 102, 1669. 
3. Davidson, B. S. Chem. Rev. 1993, 93, 1771. 
4. For some selected references, see: (a) Worayuthakarn, R.; Thasana, N.; Ruchirawat, S. Org. 
Lett. 2006, 8, 5845. (b) Csomós, P.; Martinek, T. A.; Lázár, L.; Fülöp, F. ARKIVOC 2003, 
(v), 87. (c) Heydenreich, M.; Koch, A.; Lázár, L.; Szatmári, I.; Sillanpää, R.; Kleinpeter, E.; 
Fülöp, F. Tetrahedron 2003, 59, 1951. (d) Allin, S. M.; James, S. L.; Martin, W. P.; Smith, 
T. A. D. Tetrahedron Lett. 2001, 42, 3943. (e) Ruchirawat, S.; Mutarapat, T. Tetrahedron 
Lett. 2001, 42, 1205. (f) Zalán, Z.; Hetényi, A.; Lázár, L.; Fülöp, F. Tetrahedron 2005, 61, 
5287. (g) Nyerges, M.; Tőke, L. Tetrahedron Lett. 2005, 46, 7531. (h) Lee, Y. S.; Kang, D. 
W.; Lee, S. J.; Park, H. J. Org. Chem. 1995, 60, 7149. (i) Padwa, A.; Heidelbaugh, T. M.; 
Issue in Honor of Prof Henk C. van der Plas ARKIVOC 2009 (vi) 48-62 
ISSN 1551-7012 Page 62 ©ARKAT USA, Inc. 
Kuethe, J. T.; McClure, M. S. J. Org. Chem. 1998, 63, 6778. (j) Katritzky, A. R.; Mehta, S.; 
He, H.-Y. J. Org. Chem. 2001, 66, 148. (k) Zhao, B.-X.; Eguchi, S. J. Chem. Soc., Perkin 
Trans. 1 1997, 2973. (l) Li, W.-D. Z.; Yang, H. Tetrahedron 2005, 61, 5037. (m) Padwa, A.; 
Waterson, A. G. J. Org. Chem. 2000, 65, 235. (m) Sieck, O.; Ehwald, M.; Liebscher, J. Eur. 
J. Org. Chem. 2005, 663. (n) Kleizienė, N.; Degutytė, R.; Berg, U.; Šačkus, A. J. Chem. 
Res. 2004, 370. 
5. (a) Degutytė, R.; Šačkus, A.; Berg, U. J. Chem. Res. (S) 2001, 540. (b) Valaityte, E.; 
Martynaitis, V.; Šačkus, A. Chem. Heterocycl. Comp. 2004, 40, 1465. (c) Beke, D.; Töke, L. 
Chem. Ber. 1962, 95, 2122. 
6. Houlihan, W. J.; Manning, R. E. U.S. Patent 3,551,411; Chem. Abstr. 1972, 77, 48537x. 
7. Dumčiūtė, J.; Martynaitis, V.; Holzer, W.; Mangelinckx, S.; De Kimpe, N.; Šačkus, A. 
Tetrahedron 2006, 62, 3309. 
8. For some recent examples on the synthesis of 1,3,4-oxadiazoles, see: (a) Dolman, S. J.; 
Gosselin, F.; O’Shea, P. D.; Davies, I. W. J. Org. Chem. 2006, 71, 9548. (b) Levins, C. G.; 
Wan, Z.-K. Org. Lett. 2008, 10, 1755. 
9. (a) Thomas, J. Ger. Offen. DE 2403357, 1974; Chem. Abstr. 1974, 81, 136153. (b) 
Adelstein, G. W.; Yen, C. H.; Dajani, E. Z.; Bianchi, R. G. J. Med. Chem. 1976, 19, 1221. 
10. Yale, H. L.; Losee, K. J. Med. Chem. 1966, 9, 478. 
11. Ghiran, D.; Schwartz, I.; Simiti, I. Farmacia 1974, 22, 141. 
12. (a) Ezquerra, J.; Builla, J. A. J. Heterocycl. Chem. 1986, 23, 1151. (b) Wander, A. 
GB916507, 1963; Chem. Abstr. 1963, 59, 21707. 
13. Braun, S.; Kalinowski, H.-O.; Berger, S. 150 and More Basic NMR Experiments; Wiley-
VCH: Weinheim, 1998. 
14. Northrop, R. C., Jr.; Russ, P. L. J. Org. Chem. 1975, 40, 558. 
15. Appel, R.; Kleinstuck, R.; Ziehn, K. D. Chem. Ber. 1971, 104, 1335. 
16. Wu, C.; Anderson, C. E.; Bui, H.; Gao, D.; Holland, G. W.; Kassir, J.; Li, W.; Wang, J.; 
Dupre, B. PCT Int. Appl. 078114, 2004; Chem. Abstr. 2004, 141, 277630. 
17. Borg, S.; Estenne-Bouhtou, G.; Luthman, K.; Csöregh, I.; Hesselink, W.; Hacksell, U. J. 
Org. Chem. 1995, 60, 3112 and references cited therein. 
18. Hamlyn, R.; Huckstep, M.; Earnshaw, C. G.; Stokes, S.; Tickle, D.; Allart, B.; Boyd, J. W.; 
Knutsen, L. J. S.; Lynch, R.; Patient, L. PCT Int. Appl. 082354, 2006; Chem. Abstr. 2006, 
145, 210899. 
19. Gonzales, J. E., III; Termin, A. P.; Martinborough, E.; Zimmerman, N. PCT Int. Appl. 
013914, 2005; Chem. Abstr. 2005, 142, 240421. 
20. Werner, L. H. U.S. Patent 3,480,714, 1969; Chem. Abstr. 1970, 72, 43485. 
21. Levi, M.; Ivanov, C.; Dryanska, M.; Pavlova, A. Khim.-Farm. Zh. 1971, 5, 33; Chem. Abstr. 
1971, 75, 35672.  
 
